4BIO Capital — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Actithera develops a chemistry platform for targeted cancer treatment that optimizes radiation dose absorption in tumors while reducing exposure to healthy tissue, with flexibility to pair different radionuclides based on tumor characteristics.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Darshan Dalal(Chief Medical Officer)in
Co-investorsHadean VenturesM VenturesSofinnova PartnersBioqube Ventures
Trogenix develops precision gene therapies for cancer using its Odysseus platform and Synthetic Super-Enhancer (SSE) technology, engineered DNA elements activated only in diseased cell states to selectively target and kill tumour cells while activating the immune system.
BiotechDeep TechHealthtech
Co-investorsAIN VenturesCalculus Capital Ltd.IQ CapitalLongeVC
.jpeg){kind=logo}
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.